Advanced Search

Home > Journals > International Angiology > Past Issues > International Angiology 2012 April;31(2) > International Angiology 2012 April;31(2):176-80

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEINTERNATIONAL ANGIOLOGY

A Journal on Angiology


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899

 

International Angiology 2012 April;31(2):176-80

 ORIGINAL ARTICLES

Plasminogen activator inhibitor -1 levels in patients with primary varicose vein

Erguzel N. 1, Yetkin E. 1, Erdem G. 2, Erdil N. 3, Yetkin G. 4, Heper G. 1, Celik T. 5, Senen K. 1

1 Department of Cardiology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey;
2 Department of Microbiology, SSK Diskapi Education Hospital, Ankara, Turkey;
3 Department of Cardiovascular Surgery, Inonu University Faculty of Medicine, Malatya, Turkey;
4 Department of Microbiology, Faculty of Medicine, Abant Izzet Baysal University, Bolu Turkey;
5 Department of Cardiology, Gulhane Military Hospital, Ankara, Turkey

AIM: Plasmin is involved in extracellular matrix remodeling by activating some matrix metallo-proteinases and degrading extracellular matrix; therefore component of fibrinolytic system such as tissue plasminogen activator and plasminogen activators inhibitors (PAI-1) might have a role in the pathogenesis of vascular remodeling. In our study we aimed to investigate the levels of PAI-1 levels in patients with primary varicose veins (VV) and in their age and gender matched control group.
METHODS: Forty-one consecutive patients with peripheral varicose veins and 37 healthy age and gender-matched control subjects were included in the study from the outpatient cardiology and cardiovascular surgery clinic. Study population consisted of 41 consecutive patients who met the inclusion criteria and diagnosed as having class II primary VV according to CEAP classification. Routine biochemical and hematological analysis were performed in all patients and control subjects.
RESULTS: Plasma levels of PAI-1 were found to be lower in patients than those in control subjects (5.19±2.2 ng/mL vs. 6.47±2.6 ng/mL, P=0.025). Logistic regression analysis revealed that only the plasma levels of PAI-1 were found to be independently but inversely associated with the presence of primary VVs (Odds ratio: 0.80 CI: 0.64-0.99, P=0.04).
CONCLUSION: We have shown that PAI-1 levels are significantly decreased in patients with pVVs and it has an independent association with the presence of pVVs. However, its exact relation and role via matrix metlalloproteinases on the pathogenesis of the disease remains to be elucidated in further studies.

language: English


FULL TEXT  REPRINTS

top of page